Q-omics provides the consensus-scored NCF2 profile across patient tissues and cancer cell-line models. NCF2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, NCF2 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, NCF2 protein abundance shows 41,103 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight CESC, HNSC, and LSCC as cancer lineages where NCF2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NCF2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NCF2 survival associations across molecular data types. NCF2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NCF2 RNA expression–survival associations across cancer types. High NCF2 expression shows unfavorable associations in LGG, LIHC and UVM, but favorable associations in CESC, SKCM and UCEC. The CESC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for NCF2 RNA expression.
This table summarizes NCF2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 11. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NCF2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NCF2 shows lower tumor expression in LUAD and LUSC and higher tumor expression in HNSC, KIRC, THCA and KIRP. The HNSC box plot shows higher NCF2 RNA expression in tumor versus normal tissue (log2 FC = +2.406, t-test p < 0.001).
This table shows molecular features associated with NCF2 in patient tissues and cancer cell lines. In patient samples, NCF2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, NCF2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
